Fospropofol
drugOn this page
Summary
Fospropofol (CHEMBL1201766) is an approved small molecule; indicated across 38 conditions including atrial fibrillation and hypertensive disorder.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Indications: 38 conditions
- Clinical trials: 7
- Chemistry: 288.28 Da · C13H21O5P
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201766 |
| Name | Fospropofol |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | no |
| PubChem CID | 3038498 |
| Molecular formula | C13H21O5P |
| Molecular weight | 288.28 |
| InChIKey | QVNNONOFASOXQV-UHFFFAOYSA-N |
SMILES: CC(C)C1=C(C(=CC=C1)C(C)C)OCOP(=O)(O)O
IUPAC name: [2,6-di(propan-2-yl)phenoxy]methyl dihydrogen phosphate
Also known as: Fospropofol, FOSPROPOFOL
Parent form; salt/anhydrous children: CHEMBL2021422
Patent coverage: 78 distinct patent families (175 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
38 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| atrial fibrillation | 3 | MONDO:0004981 | EFO:0000275 |
| hypertensive disorder | 3 | MONDO:0005044 | EFO:0000537 |
| severe acute respiratory syndrome | 3 | MONDO:0005091 | EFO:0000694 |
| stroke disorder | 3 | MONDO:0005098 | EFO:0000712 |
| subarachnoid hemorrhage | 3 | MONDO:0005099 | EFO:0000713 |
| obesity disorder | 3 | MONDO:0011122 | EFO:0001073 |
| cirrhosis of liver | 3 | MONDO:0005155 | EFO:0001422 |
| ischemia reperfusion injury | 3 | MONDO:0005203 | EFO:0002687 |
| heart disorder | 3 | MONDO:0005267 | EFO:0003777 |
| male reproductive organ cancer | 3 | MONDO:0005836 | EFO:0007355 |
| delirium | 3 | MONDO:0045057 | EFO:0009267 |
| acute respiratory distress syndrome | 3 | MONDO:0006502 | EFO:1000637 |
| respiratory failure | 3 | MONDO:0021113 | HP:0002093 |
| brain injury | 3 | MONDO:0043510 | MONDO:0043510 |
| coronary artery disorder | 2 | MONDO:0005010 | EFO:0001645 |
| injury | 2 | MONDO:0021178 | EFO:0000546 |
| leukemia | 2 | MONDO:0005059 | EFO:0000565 |
| hypotensive disorder | 2 | MONDO:0005468 | EFO:0005251 |
| colon adenocarcinoma | 2 | MONDO:0002271 | EFO:1001949 |
| tonsillitis | 2 | MONDO:0001039 | MONDO:0001039 |
| neoplasm | 2 | MONDO:0005070 | MONDO:0004992 |
| migraine disorder | 2 | MONDO:0005277 | MONDO:0005277 |
| morbid obesity | 1 | MONDO:0005139 | EFO:0001074 |
| chronic kidney disease | 1 | MONDO:0005300 | EFO:0003884 |
| tethered spinal cord syndrome | 1 | MONDO:0006995 | EFO:1001210 |
| kidney failure | 1 | MONDO:0001106 | EFO:1002048 |
| colorectal neoplasm | 1 | MONDO:0005335 | MONDO:0005575 |
| depressive disorder | 0 | MONDO:0002050 | MONDO:0002050 |
10 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 7.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 4 |
| Not specified | 2 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06251999 | PHASE4 | NOT_YET_RECRUITING | Efficacy and Safety of Fospropofol for Same-day Bidirectional Endoscopy in Elderly Patients |
| NCT06573489 | PHASE4 | RECRUITING | Efficacy and Safety of Fospropofol in Adult Laparoscopic Surgery: A Clinical Trial |
| NCT01401049 | PHASE4 | COMPLETED | Preventing Propofol Injection Pain: Prospective Randomized Trial Comparing Propofol Versus Fospropofol |
| NCT06344325 | PHASE4 | COMPLETED | ED90 of Fospropofol Disodium in Induction and Maintenance of Anesthesia |
| NCT00209521 | PHASE2 | COMPLETED | Comparison of AQUAVAN® Injection to DISOPRIVAN® Injectable Emulsion for Anesthesia During Coronary Artery Surgery |
| NCT01289483 | Not specified | WITHDRAWN | Fospropofol for Sedation During Elective Awake Intubation |
| NCT06261996 | Not specified | COMPLETED | Safety and Efficacy of Fospropofol vs Propofol During Invasive Mechanical Ventilation. |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: atrial fibrillation, hypertensive disorder, severe acute respiratory syndrome, stroke disorder, subarachnoid hemorrhage, obesity disorder, cirrhosis of liver, ischemia reperfusion injury, heart disorder, male reproductive organ cancer, delirium, acute respiratory distress syndrome, respiratory failure, brain injury